Given that the metastatic lesion in prostate cancers are prone to be osteoblastic instead of osteolytic, the correlation between TP53/OPG expression and overall survival could point to the possibility that low expression of TP53 and high expression of OPG in prostate cancer would induce the enhancement of bone density and set up a metastatic niche. Here, TNFRSF11B is linked to prostate carcinoma.